Last reviewed · How we verify
NCT05628272
MNCs for Bone Marrow Failure After Malignant Diseases Children Chemotherapy
NA trial testing Intravenous infusion of cord blood mononuclear cells in Cord in 20 participants. Status unknown.
1 September 2024
Quick facts
| Lead sponsor | Qianfoshan Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 October 2022 |
| Primary completion | 1 September 2024 |
| Estimated completion | 1 September 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Intravenous infusion of cord blood mononuclear cells
- application of granulocyte stimulating factor — full drug profile →
Conditions studied
- Cord — all drugs for Cord →
Sponsor
Qianfoshan Hospital
Who can join
Adults 1 to 17, any sex, with Cord. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project aims to investigate the therapeutic and repair effects of cord blood mononuclear cells (MNCs) on bone marrow failure after chemotherapy in children with malignant diseases. It is planned to collect 20 malignant children with bone marrow failure after chemotherapy and randomly divide them into two groups. The umbilical cord blood mononuclear cells were injected, ≥1×10\^8 per infusion, once a week, and the recovery time of peripheral blood leukocytes, neutrophils, platelets and hemoglobin was observed. According to the recovery of myelosuppression, stop when the peripheral blood reaches leukocytes\>1×10\^9/L, neutrophils\>0.5×10\^9/L, platelets\>25×10\^9/L, and hemoglobin\>60g/L at the same time. Use, share 1-4 times. Statistical software was used to compare the changes of peripheral blood leukocytes, neutrophils, platelets and hemoglobin before the start of the test (0d) and 1d, 3d, 5d, 7d, 10d, and 14d after the start of the test, as well as the severity of concurrent infections and antibiotic use Time, number of infusions of blood products.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05628272
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Qianfoshan Hospital trials
Trials by the same sponsor.
- NCT05727618 — The Effect of Pituitrin on the Patients With Pulmonary Hypertension Undergoing Cardiac Surgery · NA · suspended
- NCT06837831 — Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin · NA · recruiting
- NCT07260760 — Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke · not yet recruiting
- NCT07362667 — A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA · recruiting
- NCT07271849 — Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05628272 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qianfoshan Hospital
- Last refreshed: 28 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05628272.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing